Triangle Pharmaceuticals (VIRS) Release: Once-A-Day Haart Regimen Containing Coviracil(R) (Emtricitabine) Shows Potent Antiviral Activity In HIV-Infected Patients
Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced that researchers from the Agence Nationale de Recherche sur le SIDA (ANRS) in France will present preliminary data today from a pilot study. The data demonstrate that a once-a-day HAART (highly active antiretroviral therapy) regimen combining Coviracil(R) (emtricitabine), didanosine (ddI) and efavirenz has potent antiviral activity and is well tolerated in HIV-infected patients who have not previously received therapy. At a major scientific conference, Jean-Michel Molina, M.D., on behalf of the ANRS, will present data from the 24-week study. Coviracil, an antiviral compound under development by Triangle, is being evaluated by the Company in pivotal Phase II/III trials for HIV and in Phase I/II trials for hepatitis B.
(See press release) (2/1/00)
FDA Requests Additional Drug Studies From Triangle Pharmaceuticals (VIRS)
Shares of Triangle Pharmaceuticals sank 23 percent Friday after the specialty pharmaceutical firm said that the U.S. Food and Drug Administration has requested additional studies for an HIV drug candidate. Shares of the Durham, N.C.-based company (VIRS: news, msgs) plunged 3 5/8 to close at 12.
(See Story from CBS MarketWatch) (12/13/99)
Triangle Pharmaceuticals (VIRS) Announces That Additional Phase III Studies For Coactinon(R) (Emivirine) Are Required -- Stock Off -23.2% On Friday At Market Close
Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today announced that the Food and Drug Administration (FDA), following extensive discussions with the Company, has advised Triangle that it would need to conduct one or possibly two additional Phase III studies in order to prove that regimens containing Coactinon are equivalent or superior to current first line regimens used to treat HIV-infected patients. Over the first half of 2000, Triangle Pharmaceuticals will review the results of an ongoing study, MKC-401, which compares the use of Coactinon in conjunction with stavudine and Coviracil(R) (emtricitabine) with a regimen of abacavir, stavudine and Coviracil.
(See Story from Bloomberg) (12/10/99)
Explains the stagnation.
Jack |
